VU 0357121Positive allosteric modulator of mGlu5 CAS# 433967-28-3 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 433967-28-3 | SDF | Download SDF |
| PubChem ID | 2296132 | Appearance | Powder |
| Formula | C17H17F2NO2 | M.Wt | 305.32 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (163.76 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-butoxy-N-(2,4-difluorophenyl)benzamide | ||
| SMILES | CCCCOC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)F | ||
| Standard InChIKey | AHCYOTLTLQTPSU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H17F2NO2/c1-2-3-10-22-14-7-4-12(5-8-14)17(21)20-16-9-6-13(18)11-15(16)19/h4-9,11H,2-3,10H2,1H3,(H,20,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Positive allosteric modulator of mGlu5 receptors (EC50 = 33 nM). Binds to a site distinct from that bound by MPEP. |
VU 0357121 Dilution Calculator
VU 0357121 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2753 mL | 16.3763 mL | 32.7525 mL | 65.505 mL | 81.8813 mL |
| 5 mM | 0.6551 mL | 3.2753 mL | 6.5505 mL | 13.101 mL | 16.3763 mL |
| 10 mM | 0.3275 mL | 1.6376 mL | 3.2753 mL | 6.5505 mL | 8.1881 mL |
| 50 mM | 0.0655 mL | 0.3275 mL | 0.6551 mL | 1.3101 mL | 1.6376 mL |
| 100 mM | 0.0328 mL | 0.1638 mL | 0.3275 mL | 0.6551 mL | 0.8188 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
VU0357121 is a novel positive and highly selective allosteric modulator (PAM) of mGlu5R with EC50 of 33 nM.
- 3-O-Acetyloleanolic acid
Catalog No.:BCN5486
CAS No.:4339-72-4
- Toddaculine
Catalog No.:BCN3639
CAS No.:4335-12-0
- Boc-Tyr-OMe
Catalog No.:BCC3459
CAS No.:4326-36-7
- 6-Hydroxykaempferol
Catalog No.:BCN3334
CAS No.:4324-55-4
- Formoterol Hemifumarate
Catalog No.:BCC4349
CAS No.:43229-80-7
- Fenbendazole
Catalog No.:BCC1236
CAS No.:43210-67-9
- Skp2 Inhibitor C1
Catalog No.:BCC6298
CAS No.:432001-69-9
- 6-(5-Chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one
Catalog No.:BCC8753
CAS No.:43200-81-3
- Zopiclone
Catalog No.:BCC9195
CAS No.:43200-80-2
- Allylestrenol
Catalog No.:BCC8814
CAS No.:432-60-0
- SJ 172550
Catalog No.:BCC2416
CAS No.:431979-47-4
- 7'-O-Ethylmarmin
Catalog No.:BCC8274
CAS No.:
- Ethisterone
Catalog No.:BCC4478
CAS No.:434-03-7
- Methenolone acetate
Catalog No.:BCC9028
CAS No.:434-05-9
- Oxymetholone
Catalog No.:BCC4692
CAS No.:434-07-1
- Lithocholic Acid
Catalog No.:BCC3805
CAS No.:434-13-9
- Nandrolone
Catalog No.:BCC9086
CAS No.:434-22-0
- Dacarbazine
Catalog No.:BCC1174
CAS No.:4342-03-4
- K 41498
Catalog No.:BCC5867
CAS No.:434938-41-7
- L-5-Hydroxytryptophan
Catalog No.:BCC8106
CAS No.:4350-09-8
- H-Arg(Tos)-OH
Catalog No.:BCC2867
CAS No.:4353-32-6
- 5-Hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
Catalog No.:BCC8350
CAS No.:4354-76-1
- (-)-Curine
Catalog No.:BCN2673
CAS No.:436-05-5
- Diffractic Acid
Catalog No.:BCN8506
CAS No.:436-32-8
[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]
Ned Tijdschr Geneeskd. 2017;161:D861.
On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.
Why is it (also) so difficult to legislate gambling in Spain? 'Deja vu' of what occurred with alcohol.[Pubmed:27749963]
Adicciones. 2016 Oct 6;28(4):189-193.
Editorial of vol 28-4.
Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.[Pubmed:20981342]
ACS Chem Neurosci. 2010 Oct 20;1(10):702-716.
We previously discovered a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGlu(5)) termed 4 N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybe nzamide (CPPHA) that elicits receptor activation through a novel allosteric site on mGlu(5), distinct from the classical mGlu(5) negative allosteric modulator (NAM) MPEP allosteric site. However, a shallow structure-activity relationship (SAR), poor physiochemical properties, and weak PAM activity at rat mGlu(5) limited the utility of CPPHA to explore allosteric activation of mGlu(5) at a non-MPEP site. Thus, we performed a functional high-throughput screen (HTS) and identified a novel mGlu(5) PAM benzamide scaffold, exemplified by VU0001850 (EC(50) = 1.3 muM, 106% Glu(max)) and VU0040237 (EC(50) = 350 nM, 84% Glu Max). An iterative parallel synthesis approach delivered 22 analogues, optimized mGlu(5) PAM activity to afford VU0357121 (EC(50) = 33 nM, 92% Glu(max)), and also revealed the first non-MPEP site neutral allosteric ligand (VU0365396). Like CPPHA, PAMs within this class do not appear to bind at the MPEP allosteric site based on radioligand binding studies. Moreover, mutagenesis studies indicate that VU0357121 and related analogues bind to a yet uncharacterized allosteric site on mGlu(5), distinct from CPPHA, yet share a functional interaction with the MPEP site.
